TABLE OF CONTENTS I
LIST OF FIGURES III
LIST OF CHARTS IV

FULL SUITE EXECUTIVE SUMMARY 1
1.1 CHINESE ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 1
1.2 COMPETITIVE ANALYSIS 3
1.3 MARKET TRENDS 5
1.4 KEY MARKET DEVELOPMENTS 6
1.5 PROCEDURE NUMBERS 7
1.6 MARKETS INCLUDED 7
1.7 KEY REPORT UPDATES 8
1.8 VERSION HISTORY 8

RESEARCH METHODOLOGY 9
2.1 RESEARCH SCOPE 9
2.2 IDATA'S 9-STEP METHODOLOGY 9
Step 1: Project Initiation & Team Selection 9
Step 2: Prepare Data Systems and Perform Secondary Research 11
Step 3: Preparation for Interviews & Questionnaire Design 12
Step 4: Performing Primary Research 13
Step 5: Research Analysis: Establishing Baseline Estimates 15
Step 6: Market Forecast and Analysis 16
Step 7: Identify Strategic Opportunities 18
Step 8: Final Review and Market Release 19
Step 9: Customer Feedback and Market Monitoring 20

PROCEDURE NUMBERS 21
3.1 BONE GRAFT SUBSTITUTE PROCEDURE NUMBERS 21
3.1.1 Bone Graft Substitute Procedure Numbers by Material 21
3.1.2 Bone Graft Substitute Procedure Numbers by Indication 24
3.1.2.1 Bone Graft Substitute Units per Procedure by Indication 27
3.2 HYALURONIC ACID VISCOSUPPLEMENTATION PROCEDURE NUMBERS 30
3.2.1 Hyaluronic Acid Viscosupplementation Procedure Numbers by Injection Cycle 30
3.3 ORTHOPEDIC GROWTH FACTOR PROCEDURE NUMBERS 32
3.3.1 Orthopedic Growth Factor Procedure Numbers 32

APPENDIX: LOCAL COMPETITOR DIRECTORY 35
4.1 WEBSITE DIRECTORY 35

ABBREVIATIONS 37

Chart List
Chart 1 1: Orthopedic Biomaterials Market by Segment, China, 2012 - 2022 2
Chart 1 2: Orthopedic Biomaterials Market Overview, China, 2015 & 2022 2
Chart 3 1: Bone Graft Substitute Procedures by Material, China, 2012 - 2022 23
Chart 3 2: Bone Graft Substitute Procedures by Indication, China, 2012 - 2022 26
Chart 3 3: Total Bone Graft Substitute Units Sold per Procedure by Indication (Excluding Autograft), China, 2012 - 2022 29
Chart 3 4: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, China, 2012 - 2022 31
Chart 3 5: Orthopedic Growth Factor Procedures, China, 2012 - 2022 33

Figure List
Figure 1 1: Orthopedic Biomaterials Market Share Ranking by Segment, China, 2015 3
Figure 1 2: Companies Researched in this Report, China, 2015 4
Figure 1 3: Factors Impacting the Orthopedic Biomaterials Market by Segment, China 5
Figure 1 4: Recent Events in the Orthopedic Biomaterials Market, China, 2012 - 2015 6
Figure 1 5: Orthopedic Biomaterials Procedures Covered, China, 2015 7
Figure 1 6: Orthopedic Biomaterials Markets Covered, China, 2015 7
Figure 1 7: Key Report Updates, China, 2013 & 2016 8
Figure 1 8: Version History 8
Figure 3 1: Bone Graft Substitute Procedures by Material, China, 2012 - 2022 22
Figure 3 2: Bone Graft Substitute Procedures (Excluding Autograft Procedures) by Indication, China, 2012 - 2022 25
Figure 3 3: Total Bone Graft Substitute Units Sold by Indication (Excluding Autograft), China,
2012 - 2022 (10cc) 28
Figure 3 4: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, China, 2012 - 2022 31
Figure 3 5: Orthopedic Growth Factor Procedures, China, 2012 - 2022 32

Companies
The "Chinese Market Report Suite for Orthopedic Biomaterials 2016 - MedSuite" includes analysis on the following companies currently active in this market:
• Allgens Medical
• Biocomposites
• Biolu Biomaterials
• Bloomage Freda Biopharm
• Datsing Biotech
• DePuy Synthes
• FocusChem
• Genzyme
• Guona Keji
• Hanghzhou Gallop
• Harbin Gloria Pharmaceutical
• Jinxingda Company (Tianjin)
• Kaisha
• Kunming Baker Norton
• Kunming Baker Norton
• Medtronic
• Meiji Seika
• Novabone
• Osteolink Biomaterials
• Rebone Biomaterials
• Seikagaku
• Shanghai Anjiu Biotechnology
• Shanghai HaoHai
• Shanghai Jingfeng Pharmaceutical
• Shanxi OsteoRad Biomaterial
• Wright Medical
• Xin Kang Chen
• Yunkanghengye
• *Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.